Advanced melanoma trial when Keytruda alone is not enough

Advanced melanoma trial when Keytruda alone is not enough

Publication date: Dec 26, 2018

Patients with metastatic melanoma have faced grim prospects: the American Cancer Society says the five-year survival rate is only 15 percent.



Please signin to view all article content and metadata.


Leave a Comment

Your email address will not be published. Required fields are marked *